Want to join the conversation?
$AGN CEO Brent Saunders stated that in 4Q15, it enhanced category leadership through the Anterios acquisition, a licensing agreement with Mimetogen and research collaboration with Rugen Therapeutics. The company has made progress with Teva on the planned divestiture of its Global Generics business.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?